Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.

Slides:

Advertisements

Similar presentations

Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis

Advertisements

A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

A Pilot Trial of Unrelated Cord Blood Transplantation (UCBT) and Unmatched Human Placental Derived Stem Cells (HPDSC) in Children and Young Adults with.

Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

How to Treat MDS without Stem Cell Transplantation

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation Utilizing CD34 Enrichment and T Cell Addback in Children, Adolescents & Adults with.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

A Pilot Study of Unrelated Cord Blood (UCB) Transplantation and Unmatched Human Placental Derived Stem Cells (HPDSC) in Pediatric Malignant and Non-Malignant.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Biology of Blood and Marrow Transplantation

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Standardized CD3+ Cell Dose for Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT): An Interim Analysis Muhammad Omer Jamil, MD, Ayman Saad, MD,

Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.

Sabina Kersting, Leo F. Verdonck

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.

Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival Ashok Srinivasan, William Mitchell,

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.

Safety & Efficacy of Liposomal Amphotericin B Followed By Micafungin to Prevent Invasive Fungal Infection in Pediatric Allogeneic Stem Cell Transplantation.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Biology of Blood and Marrow Transplantation

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease Anna B. Pawlowska, Jerry C. Cheng,

Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback.

Potential Use of Human Placenta Derived Stem Cell (HPDSCs) As a Novel Stem Cell Source for the Treatment of Recessive Dystrophic Epidermolysis Bullosa.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas Haein Park, Aradhana Awasthi, Janet Ayello,

Members of the Intestinal Microbiota Are Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Jonathan U. Peled, MD, PhD,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children.

Neurocognitive & Neurological Outcomes in Children, Adolescents & Young Adults with High-Risk SCD Who Have Undergone Familial Haploidentical (FHI) Allosct.

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

Integrative Therapy Use as a Comfort Measure with BMT Patients

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

A Successful Approach to Decreasing Central Line Associated Blood Stream Infections Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.

Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Does Cryopreserved Hematopoietic Stem Cell Product Need an Expiration Date? Recipients Engrafted Despite Infusion of Products over Five Years in Storage.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

A Low Incidence of Nontuberculous Mycobacterial Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients Elif Unal, Catherine Yen,

Mammen Chandy Biology of Blood and Marrow Transplantation

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Biology of Blood and Marrow Transplantation

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD)

Biology of Blood and Marrow Transplantation

Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives Kirshma Khemani,

Presentation transcript:

Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation in Patients with High Risk Sickle Cell Disease (SCD) Darcy Hamill, DO, Lee Ann Baxter-Lowe, PhD, Shalini Shenoy, MD, Theodore B. Moore, MD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, MSN, CPNP, Phyllis Brand, RN, MPH, Janet Ayello, MS, MT(ASCP), Cori Abikoff, MD, Carmella van de Ven, MS, Mitchell S. Cairo, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S95-S96 (March 2016) DOI: 10.1016/j.bbmt.2015.11.396 Copyright © 2016 Terms and Conditions

Figure 1A Biology of Blood and Marrow Transplantation 2016 22, S95-S96DOI: (10.1016/j.bbmt.2015.11.396) Copyright © 2016 Terms and Conditions

Figure 1B Biology of Blood and Marrow Transplantation 2016 22, S95-S96DOI: (10.1016/j.bbmt.2015.11.396) Copyright © 2016 Terms and Conditions